FDA-BCAN Workshop: Endpoints for the Development of Neoadjuvant Systemic Therapy Regimens for Muscle-Invasive Bladder Cancer - 08/08/2019 - 08/08/2019
This workshop focuses on endpoints for the development of systemic neoadjuvant therapies for the treatment of muscle-invasive bladder cancer.
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: FDA Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Drugs & Pharmacology | Neoadjuvant Therapy | Workshops